Our proprietary technology platform, CORRECTx^™, leverages the power and precision of RNA binding systems and AAV delivery, which provides the durable effect of a one-time gene therapy. The CORRECTx^™ platform is modular and versatile with several different RNA targeting systems that can be used to modify disease-causing RNA via multiple mechanisms, including Destruction, Blocking, Splicing (Exon Skipping), and RNA Editing. Our platform also enables multi-targeting to enhance specificity or expand targeting. CorrectX offers features that address the limitations of DNA-targeted gene therapies, as well as other RNA-targeted approaches, and may lead to new genetic medicines for patients with neurodegenerative and neuromuscular diseases.